Glycomics or Glycobiology Global Market Report 2024

The global glycomics or glycobiology market has grown rapidly in recent years. It will grow from $1.59 billion in 2023 to $1.84 billion in 2024 at a compound annual growth rate (CAGR) of 15.6%. Historical growth can be attributed to the heightened awareness of glycans within biological systems, the expansion of glycan-related databases and resources, an increase in collaborative research initiatives, advancements in glycan synthesis and engineering techniques, and the identification of glycan biomarkers.

The global glycomics or glycobiology market is expected to see rapid growth in the next few years. It will grow to $3.38 billion in 2028 at a compound annual growth rate (CAGR) of 16.4%. The projected growth in the forecast period is driven by the advancement of glycan-focused artificial intelligence (AI) and data analytics, the expansion of glycobiology-based drug development, the integration of glycomics in disease biomarker discovery, and the utilization of personalized medicine and glycan-based therapeutics. Major trends expected during this period encompass cross-disciplinary collaborations between scientific fields, a deeper exploration of glycosylation patterns in disease mechanisms, the emergence of innovative precision medicine and personalized therapies utilizing glycobiology insights, advancements in glycoanalytical tools and technologies, and the utilization of glycans in the development of immunotherapy and vaccines.

The surge in demand for medications catering to severe chronic diseases is poised to drive the growth of the glycomics or glycobiology market. Chronic diseases, which persist over the long term without definitive cures, prompt extensive research into glycomics to understand glycosylation changes and their functional implications in drug development for these conditions. According to the American Cancer Society's Cancer Facts and Figures 2022-2024, the number of cancer survivors, considered a chronic disease, is projected to increase from 22.5 million in 2032 to an estimated 26 million by 2040. Hence, the escalating demand for medications to treat severe chronic diseases acts as a significant driver for the glycomics or glycobiology market.

The rising need for pharmaceutical products is expected to be a major driver for the growth of the glycomics or glycobiology market. These products encompass drugs specifically formulated to diagnose, prevent, treat, or cure various medical conditions. Glycomics and glycobiology play crucial roles in pharmaceutical development by elucidating disease mechanisms, identifying therapeutic targets, and optimizing drug design and effectiveness. According to the European Federation of Pharmaceutical Industries and Associations (EFPIA), the total pharmaceutical production in Europe surged to $384,200 million (€340,000 million) in 2022, marking a significant 4.95% increase from the preceding year's $366,267 million (€323,950 million). Consequently, the heightened demand for pharmaceutical products acts as a catalyst propelling the glycomics or glycobiology market's growth.

A prevailing trend in the glycomics or glycobiology market is the emphasis on investments in research and development (R&D) endeavors. Prominent research institutions are channeling funding into glycobiology research centers, aiming to further advancements in glycomics or glycobiology. For instance, Griffith University's Institute for Glycomics unveiled the ACRF International center for Cancer Glycomics in August 2022. This pioneering facility, established with a $2.6 million ACRF grant, is dedicated to unraveling cancer glycocoding. It is envisioned as a unique resource, driving enhanced understanding of the glycocode and translating discoveries into clinical outcomes, ultimately improving the lives of cancer patients.

Leading companies within the glycomics or glycobiology market are innovating by developing cutting-edge products like glycan screening kits to cater to expanded customer bases and augment revenue streams. Glycan Screening Kits are specialized tools designed for comprehensive immunofluorescence detection of glycan expression in tissue sections, aiding researchers in characterizing complex glycans for insights into disease biomarkers and protein modifications. Vector Laboratories Inc., in July 2022, introduced its breakthrough product, the Glysite Scout Glycan Screening Kits. These fully integrated immunofluorescence kits offer robust capabilities for profiling glycan expression in tissue sections. The kits empower researchers to gain valuable insights into the significance of glycomics in samples, particularly in understanding post-translational protein modifications and disease biomarkers. With curated lectin selections, these kits enable the identification of major surface glycan motifs, enriching the understanding of disease progression, treatment impacts, and tissue characterization.

In January 2021, Neogen, a renowned US-based food safety company specializing in testing solutions for the food industry, completed the acquisition of Megazyme for an undisclosed sum. This strategic acquisition enabled Neogen to integrate Megazyme's product line into its portfolio, bolstering Neogen's position and enhancing its connections with key players in the food production and manufacturing sectors. Megazyme, headquartered in Ireland, is recognized for its expertise in developing and manufacturing analytical solutions, particularly in the realm of glycobiology enzyme products. Neogen's acquisition of Megazyme signifies a strategic move to expand its product offerings, leveraging Megazyme's specialized product line to further fortify Neogen's relationships with major food producers and corporations.

Major companies operating in the glycomics or glycobiology market report are Water Corporation, Aligent Technologies Inc., Bruker Corporation, Merck Co. & KgaA, New England Biolabs Inc., Danaher Corporation, Shimadzu Corporation, ProZyme Inc., Takara Bio Inc., S-BIO Pte. Ltd., Asparia Glycomics SL, Lectenz Bio, Chemily Glycoscience LLC, Z Biotech LLC, RayBiotech Inc., Thermo Fisher Scientific Inc., Promega Corporation, Bio-Techne Corp., Sumitomo Bakelite Co. Ltd., Bruker Corporation, AMS Bio LLC, Ludger Ltd., CD BioGlyco Ltd., GlycoDiag SAS, Kode Biotech Limited, Glyxera GmBH, Glycomix Ltd., IEC Group Ltd., and R&D Systems Inc.

North America was the largest region in the glycomics or glycobiology market share in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the glycomics or glycobiology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the glycomics or glycobiology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary products associated with glycomics or glycobiology include enzymes, kits, reagents and chemicals, instruments, and carbohydrates. Enzymes, as biological polymers, serve as catalysts for biochemical reactions. These products find application across various domains such as drug discovery and development, disease diagnostics, among others, and are extensively utilized within academic research institutes, pharmaceutical and biotechnology companies, as well as clinical laboratories.

This report provides glycomics or glycobiology market statistics, including glycomics or glycobiology industry global market size, regional shares, competitors with a glycomics or glycobiology market share, detailed glycomics or glycobiology market segments, market trends and opportunities, and any further data you may need to thrive in the glycomics or glycobiology industry. This glycomics or glycobiology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glycomics or glycobiology market includes revenues earned by entities by maintaining tissue structure, porosity, and integrity. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.